Shares of Xeris Biopharma Holdings, Inc. (XERS) are up 12% on Wednesday after the company announced that it has entered into an exclusive worldwide license agreement with Amgen to develop, manufacture, and commercialize a subcutaneous formulation of teprotumumab, also known as TEPEZZA.
Eris Lifesciences has announced that it has reached a definitive agreement to acquire the dermatology and nephrology branded formulations business units of Biocon Biologics in India. The deal is valued at Rs 366 crore. The acquisition will be partially funded through debt financing.
The Proportionality lore page has Saint-14 hunting down Savathun, returning to his old “monster of the Eliksni” days, killing her with his void powers, forcing Immaru to resurrect her, and killing her over and over and over again.